The Factor D complement inhibitor market is poised for significant growth, driven by expanding indications for existing therapies like danicopan and the anticipated approval of novel agents like vemircopan. This market expansion is fueled by advancements in biotechnology, increasing prevalence of autoimmune diseases, and a robust pipeline of drug candidates in clinical trials.
The HDAC inhibitors market has witnessed significant growth in recent years, driven by the promising therapeutic potential of these drugs in treating a wide range of diseases, particularly cancer and neurological disorders. HDAC inhibitors are a class of compounds that modulate gene expression by inhibiting the activity of histone deacetylases (HDACs), which in turn plays a crucial role in regulating gene expression. This regulatory mechanism has led to the exploration of HDAC inhibitors as potential therapeutic agents for various diseases, with a focus on oncology and neurology.
